Literature DB >> 18064043

Regulating Vav1 phosphorylation by the SHP-1 tyrosine phosphatase is a fine-tuning mechanism for the negative regulation of DISC formation and Fas-mediated cell death signaling.

G Koncz1, K Kerekes, K Chakrabandhu, A-O Hueber.   

Abstract

The actin cytoskeleton association is required for caspase 8-independent Fas/CD95 receptor internalization, a critical step for an optimal death-inducing signaling complex formation along the endocytic pathway, leading to efficient activation of the caspase cascade and, ultimately, cell death. However, the way in which this initiation phase of Fas receptor signaling is regulated is still unknown. We report herein that, in B cells, upon Fas engagement, the tyrosine phosphatase SHP-1-regulated Vav dephosphorylation, by downmodulating the Fas-ezrin-actin linkage is a fine-tune switch-off mechanism that the cell uses as a way to terminate the receptor internalization, controlling therefore the time and extent of the DISC formation and cell death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18064043     DOI: 10.1038/sj.cdd.4402282

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  9 in total

1.  Vav protein guanine nucleotide exchange factor regulates CD36 protein-mediated macrophage foam cell formation via calcium and dynamin-dependent processes.

Authors:  S Ohidar Rahaman; Gang Zhou; Roy L Silverstein
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

2.  The distinct role of guanine nucleotide exchange factor Vav1 in Bcl-2 transcription and apoptosis inhibition in Jurkat leukemia T cells.

Authors:  Jie Yin; Ya-juan Wan; Shi-yang Li; Ming-juan Du; Cui-zhu Zhang; Xing-long Zhou; You-jia Cao
Journal:  Acta Pharmacol Sin       Date:  2010-12-13       Impact factor: 6.150

3.  Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection.

Authors:  Constantinos Petrovas; Benjamin Chaon; David R Ambrozak; David A Price; J Joseph Melenhorst; Brenna J Hill; Christof Geldmacher; Joseph P Casazza; Pratip K Chattopadhyay; Mario Roederer; Daniel C Douek; Yvonne M Mueller; Jeffrey M Jacobson; Viraj Kulkarni; Barbara K Felber; George N Pavlakis; Peter D Katsikis; Richard A Koup
Journal:  J Immunol       Date:  2009-06-29       Impact factor: 5.422

4.  Shp1 regulates T cell homeostasis by limiting IL-4 signals.

Authors:  Dylan J Johnson; Lily I Pao; Salim Dhanji; Kiichi Murakami; Pamela S Ohashi; Benjamin G Neel
Journal:  J Exp Med       Date:  2013-07-01       Impact factor: 14.307

Review 5.  Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and Diseases.

Authors:  Krittalak Chakrabandhu; Anne-Odile Hueber
Journal:  Front Immunol       Date:  2016-10-17       Impact factor: 7.561

6.  Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation.

Authors:  Yaw-Wen Hsu; Fu-Fei Hsu; Ming-Tsai Chiang; Dong-Lin Tsai; Fu-An Li; Takashi Angata; Paul R Crocker; Lee-Young Chau
Journal:  J Biomed Sci       Date:  2021-01-05       Impact factor: 8.410

7.  Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells.

Authors:  Paula C Soto; Maile Y Karris; Celsa A Spina; Douglas D Richman; Ajit Varki
Journal:  J Mol Med (Berl)       Date:  2012-09-04       Impact factor: 4.599

8.  Shp1 signalling is required to establish the long-lived bone marrow plasma cell pool.

Authors:  Yan-Feng Li; Shengli Xu; Xijun Ou; Kong-Peng Lam
Journal:  Nat Commun       Date:  2014-06-30       Impact factor: 14.919

9.  An Evolution-Guided Analysis Reveals a Multi-Signaling Regulation of Fas by Tyrosine Phosphorylation and its Implication in Human Cancers.

Authors:  Krittalak Chakrabandhu; Sébastien Huault; Jérôme Durivault; Kévin Lang; Ly Ta Ngoc; Angelique Bole; Eszter Doma; Benoit Dérijard; Jean-Pierre Gérard; Michel Pierres; Anne-Odile Hueber
Journal:  PLoS Biol       Date:  2016-03-04       Impact factor: 8.029

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.